Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Wen Jin Wu
  • Milos Dokmanovic
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_5962-6



Trastuzumab (US brand name: Herceptin®) is a humanized monoclonal antibody IgG1 directed against the human epidermal growth factor receptor 2 (HER2) and is approved for the treatment of HER2-positive breast cancer and HER2-positive metastatic adenocarcinomas of the stomach or gastroesophageal junction (GEJ).



Antibodies, also known as immunoglobulins, are large protein molecules produced by the body’s immune system in response to antigenic stimuli that are either infectious agents, such as a bacteria, fungi, viruses, or parasites, or other molecular components recognized by the body’s immune system as foreign. Antibodies consist of two identical pairs of polypeptide chains, comprised of a heavy chain and a...


Breast Cancer International Research Group Trastuzumab Cardiotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Dokmanovic M, Wu WJ (2011) Trastuzumab: resistance and breast cancer. In: Gunduz M, Gunduz E (eds) Breast cancer: carcinogenesis, cell growth and signaling pathways. InTech, Rijeka, pp 171–204Google Scholar
  2. Hudis CA (2007) Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 357:39–51CrossRefPubMedGoogle Scholar
  3. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243PubMedGoogle Scholar
  4. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525–3533CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2012

Authors and Affiliations

  1. 1.Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and ResearchU.S. Food and Drug AdministrationBethesdaUSA